# Recovery Blend FAQ — Wolverine, KLOW, GLOW — Core Fusion Peptides > Frequently asked questions about three Recovery & Tissue Repair research-peptide blends — Wolverine, KLOW and GLOW — answered from the peer-reviewed constituent literature, with citations. Direct, citation-anchored answers to the questions readers most often bring to the Wolverine, KLOW and GLOW research blends. ## What is the Wolverine peptide blend? The Wolverine blend is a research-community two-peptide co-formulation pairing BPC-157 — a fifteen-amino-acid gastric cytoprotective peptide — with TB-500, the synthetic seven-amino-acid actin-binding fragment of thymosin beta-4. The pairing is rationalized as complementary and non-overlapping: BPC-157 drives new blood-vessel growth via VEGFR2 activation [4], while TB-500 / thymosin beta-4 governs the cytoskeletal dynamics that let repair cells migrate toward a wound [5]. The combination has never been tested in a controlled study [2]. ## What is BPC-157 and TB-500? BPC-157 (Body Protection Compound 157) is a stable synthetic pentadecapeptide (fifteen amino acids) derived from a protein in human gastric juice, studied primarily for its pro-angiogenic and cytoprotective properties [4]. TB-500 is the synthetic Ac-LKKTETQ heptapeptide (seven amino acids) corresponding to the actin-binding region (residues 17-23) of the natural protein thymosin beta-4 [5][6]. An important naming gap: in commerce, "TB-500" means the short fragment, but most published efficacy research used full-length thymosin beta-4, which is roughly five times larger. Neither is an approved drug; both are WADA-prohibited [1]. ## What is the BPC-157 and TB-500 blend used for in research? The constituent literatures are studied most in tissue-repair contexts: tendon healing [7], angiogenesis in ischemic muscle [4], and — for the full-length thymosin beta-4 parent of TB-500 — cell migration, anti-scarring, and corneal and cardiac wound repair [5]. A 2025 systematic review of BPC-157 in orthopedic sports medicine found 35 preclinical and only 1 human study, with Level IV-V evidence and no clinical safety data [2]. No controlled study of the Wolverine combination exists for any indication [2]. ## Why are BPC-157 and TB-500 combined (the Wolverine stack)? The combination rationale is that the two mechanisms are complementary and largely non-overlapping: BPC-157 promotes new blood-vessel growth into damaged tissue (via VEGFR2-Akt-eNOS signaling) [4], while TB-500 / thymosin beta-4 regulates the actin pool that repair cells draw on to crawl into a wound [5][6]. In theory, growing the blood supply and mobilizing the repair cells address different bottlenecks in the same repair cascade. In practice, this is mechanistic reasoning from independent single-component studies — no controlled trial has established synergy, an optimal ratio, or any combination endpoint [2]. ## What is KLOW peptide? KLOW is a co-formulated four-peptide research blend combining KPV, GHK-Cu, BPC-157 and TB-500, typically supplied as a lyophilized vial with approximately 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV (80 mg total). Each peptide contributes a distinct mechanism: KPV suppresses NF-kB and MAPK inflammatory signaling via PepT1-mediated uptake [11]; GHK-Cu stimulates collagen and matrix synthesis [10]; BPC-157 drives angiogenesis [4]; and TB-500 / thymosin beta-4 governs cell migration [5]. It is not an approved drug, and no controlled study of the four-peptide combination exists [1]. ## What is KLOW peptide used for? Based on the single-component literatures, the four constituents have been studied for tendon and soft-tissue healing (BPC-157, TB-500 / thymosin beta-4), skin matrix remodeling and wound healing (GHK-Cu), and gut inflammation (KPV). A 2026 Sports Medicine review covering the blend's BPC-157 and TB-500 components concludes that animal-model promise is real but human safety data are scarce and these compounds operate outside regulatory oversight [1]. Community accounts of the four-peptide stack commonly describe recovery from nagging joint and tendon injuries, reduced general achiness, and improved gut comfort — these are anecdotal, not clinical findings. ## Where do you inject KLOW peptide? This desk does not advise on administration, dose, site, schedule or route for KLOW or any of its constituents. The question of where to inject is a medical and pharmacological one that falls outside what a research literature digest can or should answer. Community injection-site information circulating online has no basis in controlled human trials and is not reproduced here. Readers with health questions should consult a licensed clinician. ## What is GLOW peptide? GLOW is a three-peptide research blend most commonly combining GHK-Cu, BPC-157 and TB-500 — typically 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 per research vial. It shares BPC-157 and TB-500 with [Wolverine](/wolverine) and adds GHK-Cu, which gives the blend its skin-and-repair positioning. GHK-Cu is the copper-carrying tripeptide drawn from type I collagen that signals dermal fibroblasts to rebuild their collagen-and-elastin scaffolding [10][12]. GLOW is not an approved drug; no controlled study of the three-peptide combination exists [1]. ## What does the GLOW peptide do? Based on its constituent literatures, the GLOW blend's three components address complementary aspects of skin and tissue repair: GHK-Cu signals collagen, elastin, and proteoglycan synthesis and has placebo-controlled human evidence for skin tightening and reduced wrinkle depth in topical applications [10]; BPC-157 promotes new blood-vessel formation via VEGFR2 [4]; and TB-500 / thymosin beta-4 drives cell migration and anti-scarring via actin sequestration [5]. Community accounts frequently report a brighter complexion, smoother skin, and improved wound healing — these are anecdotal, not clinical findings, and no controlled study of the GLOW blend exists [1]. ## What does GLOW peptide have in it? GLOW's canonical research-vial composition is GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex), BPC-157 (the fifteen-amino-acid gastric cytoprotective peptide), and TB-500 (the synthetic Ac-LKKTETQ heptapeptide corresponding to the actin-binding region of thymosin beta-4). Exact ratios are formulation-dependent and not standardized [1]. GHK-Cu is the mass-dominant component (around 50 of 80 mg in the most commonly cited ratio), contributing both the copper-delivery and collagen-signaling arms [10][12]. The blend has no single CAS number or molecular weight. ## What peptides are in the GLOW blend? GLOW contains three peptides: **GHK-Cu** (a copper-carrying tripeptide studied for skin matrix regeneration [10][12]), **BPC-157** (a fifteen-amino-acid gastric peptide studied for angiogenesis and tissue repair [4]), and **TB-500** (the synthetic seven-amino-acid actin-binding fragment of thymosin beta-4, studied — mostly as the full parent protein — for cell migration and wound repair [5]). These are the same BPC-157 and TB-500 constituents found in [Wolverine](/wolverine), and the same GHK-Cu found in [KLOW](/klow). No additional peptides are part of the canonical GLOW formulation; KLOW adds KPV to this same three-peptide core. ## Are these blends safe? The honest answer is that no one knows, for any of the three blends, in humans. None has been tested as a combination in any controlled study. For the individual constituents: a 2025 first-in-human BPC-157 intravenous pilot in two adults found no adverse events and no safety-biomarker changes [8] — but two subjects is not a safety study. A 2026 Sports Medicine review covering BPC-157 and TB-500 / thymosin beta-4 concludes that human safety data are scarce, potential for serious harm exists, and these compounds operate outside regulatory oversight [1]. TB-500 is WADA-prohibited. For anyone with an active or recent cancer, a copper-handling disorder (such as Wilson's disease), or autoimmune disease, constituents in these blends carry specific mechanistic cautions that should be taken seriously. This desk provides research summaries, not medical advice. --- A literature digest of research-peptide blend constituents — citations and cautions, never a dose and never a product.